Table 1 Summary of Zika virus (ZIKV) vaccines under clinical development
From: Toll-like receptor response to Zika virus infection: progress toward infection control
Vaccine name | Vaccine type | Vaccine formulation/antigen | Developer/ sponsor /manufacturer | Clinical phase | Strengths | Limitations | References/clinical trial identifying number |
|---|---|---|---|---|---|---|---|
VLA1601 | Inactivated vaccine | Alum-adjuvanted inactivated whole virus vaccine | Valneva SE | Phase 1 | Safe and production of neutralizing antibodies; seroconversion rates up to 85.7% (high dose) | Seroconversion decreased to 40% after 6 months of vaccination | |
TAK-426 | Inactivated vaccine | Alum-adjuvanted inactivated ZIKV vaccine | Takeda | Phase 1 | Safe, well-tolerated, and immunogenic | Higher dose | |
ZPIV | Inactivated vaccine | Adjuvanted Zika virus purified inactivated vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Safe, well-tolerated, and immunogenic in flavivirus-naïve and primed adults | Reduced seroconversion in YFV-vaccine-primed group | 109, ClinicalTrials.gov ID NCT02963909 |
BBV121 | Inactivated vaccine | Alum-adjuvanted Zika virus purified inactivated vaccine | Bharat Biotech International Ltd. | Phase 1 | Data yet to be published | Data yet to be published | 28, ClinicalTrials.gov ID NCT04478656 |
VRC5283 | DNA vaccine | Pre-membrane and envelope (prME) region of ZIKV sequence | NIAID | Phase 1 | Safe and well-tolerated; ZIKV-specific immune response and nAb production | Mild adverse reaction | 113, ClinicalTrials.gov ID NCT02840487 |
VRC5288 | DNA vaccine | prM sequences of ZIKV and E sequences of both ZIKV and JEV | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Safe and well-tolerated; ZIKV-specific immune response and nAb production | Mild adverse reaction | 113, ClinicalTrials.gov ID NCT02996461 |
GLS-5700 | DNA vaccine | prME | GeneOne Life Science, Inc. | Phase 1 | Safe, produced nAbs | Mild adverse reaction | 114, ClinicalTrials.gov ID NCT02809443 |
mRNA-1325 Zika vaccine | mRNA vaccine | prME gene | ModernaTX, Inc. | Phase 1 | Well-tolerated | Poor ZIKV-specific nAb production | 118, ClinicalTrials.gov ID NCT03014089 |
mRNA-1893 Zika vaccine | mRNA vaccine | C/prME gene | ModernaTX, Inc. | Phase 1 | Well-tolerated, robust ZIKV-specific nAb production | Adverse reaction at higher dose | 118, ClinicalTrials.gov ID NCT04064905 |
mRNA-1893 Zika vaccine | mRNA vaccine | C/prME gene | ModernaTX, Inc. | Phase 2 | Data yet to be published | Data yet to be published | ClinicalTrials.gov ID NCT04917861 |
MV-Zika vaccine | Viral-vectored vaccine | prME proteins | Themis Bioscience GmbH | Phase 1 | Data yet to be published | Data yet to be published | ClinicalTrials.gov ID NCT02996890 |
